TELA Bio
TELA
47 hedge funds and large institutions have $81.6M invested in TELA Bio in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 15 closing their positions.
227,500% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $1K
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
79% more capital invested
Capital invested by funds: $45.6M → $81.6M (+$36.1M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 49 → 47 (-2)
4.27% less ownership
Funds ownership: 72.89% → 68.63% (-4.3%)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.46M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.96M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$4.05M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.5M |
| 5 |
RA
Royce & Associates
New York
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.47M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.89M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$501K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$290K |
| 5 |
Millennium Management
New York
|
-$277K |
TELA Hedge Fund Activity: Q4 2024 in Review
47 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q4 2024, worth a combined $81.6M — up 79% from $45.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TELA and 13 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 21 added.
The largest buyer was Silverarc Capital Management, adding an estimated $5.46M. The largest seller was OrbiMed, exiting entirely with an estimated $5.47M sold.
- 47 institutional investors held TELA Bio (TELA) as of Q4 2024, down from 49 in Q3 2024.
- Funds reported $81.6M of TELA Bio stock for Q4 2024, up 79% quarter-over-quarter.
- 13 funds opened new TELA Bio positions in Q4 2024 and 15 closed out, a net change of -2 holders.
- The largest TELA Bio buyer in Q4 2024 was Silverarc Capital Management, an estimated $5.46M added.
- The largest TELA Bio seller in Q4 2024 was OrbiMed, an estimated $5.47M sold.
Based on aggregated 13F filings for Q4 2024.